{"id":"NCT01262677","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Once-A-Day Pregabalin For Partial Seizures","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-17","primaryCompletion":"2012-07-31","completion":"2012-08-01","firstPosted":"2010-12-17","resultsPosted":"2018-06-06","lastUpdate":"2021-01-25"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Seizures","Epilepsies, Partial"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"pregabalin CR 330 mg","type":"EXPERIMENTAL"},{"label":"pregabalin CR 165 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.","primaryOutcome":{"measure":"Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase","timeFrame":"Week 0 to Week 14","effectByArm":[{"arm":"Pregabalin 165 mg","deltaMin":2.24,"sd":0.757},{"arm":"Pregabalin 330 mg","deltaMin":2.33,"sd":0.873},{"arm":"Placebo","deltaMin":2.32,"sd":0.91}],"pValues":[{"comp":"OG000 vs OG002","p":"0.9076"},{"comp":"OG001 vs OG002","p":"0.0907"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":82,"countries":["United States","Argentina","Bosnia and Herzegovina","Bulgaria","Czechia","Germany","Hong Kong","Hungary","India","Malaysia","Mexico","Poland","Puerto Rico","Romania","Russia","Serbia","Singapore","Thailand"]},"refs":{"pmids":["24962242"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081194&StudyName=Once-A-Day%20Pregabalin%20For%20Partial%20Seizures"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":100},"commonTop":["Dizziness","Fatigue","Weight increased"]}}